| Not Yet Recruiting | Probiotic Supplementation During Cytotoxic Chemotherapy for Solid Tumor Malignancies NCT06772090 | Masonic Cancer Center, University of Minnesota | N/A |
| Not Yet Recruiting | Ivermectin Combined With Immune Checkpoint Inhibition in Cancer (ICONIC) NCT07487805 | University of Florida | Phase 2 |
| Not Yet Recruiting | A Study of TIL in Advanced Solid Tumors (CZ) NCT07294872 | Shanghai Juncell Therapeutics | Phase 1 |
| Not Yet Recruiting | ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu NCT06824363 | University of California, Irvine | EARLY_Phase 1 |
| Not Yet Recruiting | UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations NCT06895681 | University of California, San Francisco | — |
| Recruiting | DESCANSO, a Mental Health Intervention for Depression, Insomnia, and Fatigue Symptoms in Latino People With Ca NCT07225088 | Memorial Sloan Kettering Cancer Center | N/A |
| Recruiting | Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM) NCT07139990 | University of Texas Southwestern Medical Center | Phase 1 |
| Active Not Recruiting | A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors NCT07159828 | Axion Bio, Inc | Phase 1 |
| Active Not Recruiting | Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Sichuan) NCT07152353 | Ion Beam Applications | N/A |
| Active Not Recruiting | Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Shenzhen) NCT07153094 | Ion Beam Applications | N/A |
| Recruiting | R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) i NCT06398418 | Rise Therapeutics LLC | Phase 1 |
| Recruiting | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors NCT07020221 | Verastem, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With S NCT06682793 | A2 Biotherapeutics Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei) NCT07137195 | Ion Beam Applications | N/A |
| Recruiting | Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tu NCT06915753 | Tyra Biosciences, Inc | Phase 1 |
| Active Not Recruiting | Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors NCT06714617 | SystImmune Inc. | Phase 1 |
| Recruiting | BBO-11818 in Adult Subjects With KRAS Mutant Cancer NCT06917079 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Phase 1 |
| Recruiting | A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours NCT06977737 | Accession Therapeutics Limited | Phase 1 / Phase 2 |
| Recruiting | AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors NCT06911333 | Avelos Therapeutics Inc. | Phase 1 / Phase 2 |
| Enrolling By Invitation | A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring NCT06788509 | Janssen Research & Development, LLC | Phase 1 |
| Recruiting | A Pilot Study of Genetic Testing Uptake Through Enhanced Oncology Nurse-Led Intervention NCT06436157 | University of California, Davis | N/A |
| Recruiting | Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4 NCT06895733 | Tianjin Medical University Second Hospital | Phase 1 / Phase 2 |
| Recruiting | Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors NCT06625775 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | Phase 1 |
| Active Not Recruiting | MVX-ONCO-2 in Advanced Solid Tumors NCT05071846 | University Hospital, Geneva | Phase 1 |
| Not Yet Recruiting | Molecular Services and EMR-Lab Integration Application (ELIA) for Reducing Healthcare Disparities in Cancer Pa NCT06090513 | Bien-Willner Physicians Group PA | — |
| Recruiting | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors NCT06617169 | Monopar Therapeutics | Phase 1 |
| Withdrawn | A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors NCT06372574 | Genentech, Inc. | Phase 1 |
| Recruiting | First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors NCT06622486 | Egle Therapeutics | Phase 1 / Phase 2 |
| Not Yet Recruiting | TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor NCT06619886 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | EARLY_Phase 1 |
| Recruiting | A Study to Determine the Effect of CT3001 in Patients with Advanced Solid Tumors NCT06598007 | Crossignal Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NCT06586957 | NiKang Therapeutics, Inc. | Phase 1 |
| Recruiting | A Study of VET3-TGI in Patients With Solid Tumors NCT06444815 | KaliVir Immunotherapeutics | Phase 1 |
| Recruiting | First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors NCT06554795 | DualityBio Inc. | Phase 1 / Phase 2 |
| Recruiting | First In Human Study of CX-801 in Advanced Solid Tumors NCT06462794 | CytomX Therapeutics | Phase 1 |
| Recruiting | Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion NCT06383884 | Samsung Medical Center | Phase 2 |
| Recruiting | Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer NCT06439888 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 1 / Phase 2 |
| Not Yet Recruiting | To Assess the Effects of Single Dose of JMKX001899 on QTc Interval in Healthy Subjects NCT06473948 | Jemincare | Phase 1 |
| Recruiting | Anti-cancer DC Cell Vaccination to Treat Solid Tumors NCT06477614 | Second Affiliated Hospital of Guangzhou Medical University | Phase 1 |
| Recruiting | Anti-cancer Neoantigen Polypeptide Vaccine to Treat Solid Tumors NCT06195293 | Second Affiliated Hospital of Guangzhou Medical University | Phase 1 |
| Recruiting | A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants Wit NCT06507306 | Kumquat Biosciences Inc. | Phase 1 |
| Recruiting | Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors NCT06337084 | Monopar Therapeutics | Phase 1 |
| Recruiting | Development and Application Study of ePRO Software for Managing Cancer Patients Throughout the Treatment Perio NCT06469268 | Shikai Wu | N/A |
| Terminated | A Phase Ib/II Study of BY101298 , an Oral DNA-PK Inhibitor, Combined with Radiotherapy in Patients with Malign NCT06524804 | Chengdu Baiyu Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms NCT06506643 | Vector Vitale LLC | Phase 1 / Phase 2 |
| Recruiting | GPC3/Mesothelin-CAR-γδT Cells Against Cancers NCT06196294 | Second Affiliated Hospital of Guangzhou Medical University | Phase 1 |
| Recruiting | Anti-cancer Neoantigen mRNA Vaccine to Treat Solid Tumors NCT06195384 | Second Affiliated Hospital of Guangzhou Medical University | Phase 1 |
| Recruiting | Autologous Tumor-Infiltrating Lymphocyte (GT307 Injection ) for Treatment of Patients With Solid Tumours NCT06397963 | Grit Biotechnology | N/A |
| Recruiting | A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs NCT06228326 | Krystal Biotech, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors NCT06326411 | Nested Therapeutics, Inc | Phase 1 |
| Recruiting | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With So NCT06051695 | A2 Biotherapeutics Inc. | Phase 1 / Phase 2 |
| Recruiting | First In Human Study of CX-2051 in Advanced Solid Tumors NCT06265688 | CytomX Therapeutics | Phase 1 |
| Unknown | Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects NCT06348290 | Jemincare | Phase 1 |
| Recruiting | Interventional Software for Multi-immunotherapy of Solid Tumors NCT06478108 | Second Affiliated Hospital of Guangzhou Medical University | Phase 2 / Phase 3 |
| Recruiting | A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors NCT06265727 | Corbus Pharmaceuticals Inc. | Phase 1 / Phase 2 |
| Recruiting | Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors NCT06218914 | AstraZeneca | Phase 1 |
| Recruiting | Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors NCT06380660 | Acerand Therapeutics (Shanghai) Limited | Phase 1 / Phase 2 |
| Recruiting | A Phase l Study of By101921, an Oral PARP7 Inhibitor, in Patients With Advanced Solid Tumors NCT06433726 | Chengdu Baiyu Pharmaceutical Co., Ltd. | Phase 1 |
| Terminated | Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors NCT06391918 | GenVivo, Inc. | Phase 1 |
| Terminated | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NCT06264921 | NiKang Therapeutics, Inc. | Phase 1 |
| Recruiting | Personalized Models for Cancer Research NCT06350539 | New York Stem Cell Foundation Research Institute | — |
| Recruiting | A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors NCT06244771 | Frontier Medicines Corporation | Phase 1 / Phase 2 |
| Recruiting | Ex Vivo Tumor Visualization and Resection Margin Assessment Using Topically Applied Fluorescent Imaging Agents NCT06292845 | Erasmus Medical Center | N/A |
| Withdrawn | Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors NCT05284214 | Partner Therapeutics, Inc. | Phase 2 |
| Terminated | Study of IK-595 in RAS- or RAF-altered Advanced Tumors NCT06270082 | Ikena Oncology | Phase 1 |
| Recruiting | Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients NCT06003621 | Omico | Phase 2 |
| Completed | Study of DF6215 in Patients With Advanced Solid Tumors NCT06108479 | Dragonfly Therapeutics | Phase 1 |
| Active Not Recruiting | HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease NCT05865990 | MedSIR | Phase 2 |
| Unknown | Clinical Study on the Treatment of Advanced Recurrent Tumors With Anticancer Mouse Characteristic Human Neutro NCT06240767 | Wuxi People's Hospital | Phase 1 |
| Unknown | Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent NCT06075849 | Panolos Bioscience | Phase 1 |
| Recruiting | A Study of Avutometinib for People With Solid Tumor Cancers NCT06104488 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Terminated | A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Soli NCT06063317 | Imugene Limited | Phase 1 |
| Recruiting | Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors NCT06088004 | Suzhou Abogen Biosciences Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial NCT06026254 | ImmuneSensor Therapeutics Inc. | Phase 1 |
| Recruiting | Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11) NCT06032845 | Fudan University | Phase 2 |
| Recruiting | GT201 Injection For The Treatment Of Advanced Solid Tumors NCT06144671 | Grit Biotechnology | Phase 1 / Phase 2 |
| Completed | Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractor NCT05990920 | NKGen Biotech, Inc. | Phase 1 |
| Recruiting | A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors NCT05866692 | TYK Medicines, Inc | Phase 1 |
| Completed | A Study of DCR-STAT3 in Adults With Solid Tumors NCT06098651 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Phase 1 |
| Recruiting | IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors NCT05958121 | Immatics Biotechnologies GmbH | Phase 1 / Phase 2 |
| Terminated | Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Can NCT05840510 | Mirati Therapeutics Inc. | Phase 1 |
| Unknown | MUC1 Therapeutic Tumor Vaccine in Advanced Solid Cancers NCT05986981 | Peking Union Medical College Hospital | Phase 2 |
| Unknown | A Study of HB0045 Injection in Patients With Advanced Solid Tumors NCT06056323 | Shanghai Huaota Biopharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study of Bio-008 in Subjects With Advanced or Metastatic Solid Tumours NCT06027346 | Shijiazhuang Yiling Pharmaceutical Co. Ltd | Phase 1 |
| Recruiting | CD70 Targeted CAR-T Cells in CD70 Positive Advanced/Metastatic Solid Tumors NCT05947487 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Recruiting | Combination of CAR-DC Vaccine and ICIs in Malignant Tumors NCT05631886 | Chinese PLA General Hospital | Phase 1 |
| Active Not Recruiting | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid NCT05864144 | Sensei Biotherapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | 64Cu-GRIP B in Patients With Advanced Malignancies NCT05888532 | Rahul Aggarwal | Phase 1 / Phase 2 |
| Recruiting | Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors NCT05868174 | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 1 |
| Active Not Recruiting | A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer NCT05678010 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Active Not Recruiting | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors NCT05736731 | A2 Biotherapeutics Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | A Phase l Study of By101298, an Oral DNA-PK Inhibitor, in Patients With Advanced Solid Tumors NCT06462716 | Chengdu Baiyu Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors NCT05689853 | Akeso | Phase 1 / Phase 2 |
| Recruiting | Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors NCT05856981 | Sairopa B.V. | Phase 1 |
| Active Not Recruiting | CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors NCT05631899 | Chinese PLA General Hospital | Phase 1 |
| Completed | First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors NCT05759949 | Relay Therapeutics, Inc. | Phase 1 |
| Recruiting | A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tu NCT05669430 | GV20 Therapeutics | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody NCT05662397 | HotSpot Therapeutics, Inc | Phase 1 / Phase 2 |
| Active Not Recruiting | A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combi NCT05763004 | ImmunOs Therapeutics AG | Phase 1 |
| Recruiting | Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers NCT05779917 | Second Affiliated Hospital of Guangzhou Medical University | Phase 1 |
| Recruiting | Clinical Nurse Specialist Led Early Palliative Survivorship Care for Patients With Advanced Cancer NCT05947695 | Good Samaritan Hospital Medical Center, New York | N/A |
| Active Not Recruiting | Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors NCT05651022 | Indaptus Therapeutics, Inc | Phase 1 / Phase 2 |
| Recruiting | PRE-I-SPY Phase I/Ib Oncology Platform Program NCT05868226 | QuantumLeap Healthcare Collaborative | Phase 1 |
| Unknown | A Study of BH009 in Head and Neck Squamous Cell Carcinoma and Ovarian Cancer NCT06232863 | Zhuhai Beihai Biotech Co., Ltd | Phase 1 |
| Unknown | A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminar NCT05442996 | Shanghai Henlius Biotech | Phase 1 |
| Unknown | Fluoride-labeled Boronophenylalanine PET Imaging in Patients With Solid Tumors NCT05538676 | Xiaohua Zhu | — |
| Terminated | Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors NCT05559541 | Akeso | Phase 1 / Phase 2 |
| Withdrawn | Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors NCT05060276 | Sorrento Therapeutics, Inc. | Phase 1 |
| Unknown | Safety Study of 177Lu-Anti-ED-B mAbs SPECT Imaging in Patients With ED-B Positive Solid Tumors NCT05623891 | Affiliated Hospital of Jiangnan University | EARLY_Phase 1 |
| Terminated | First in Human, Dose Escalation, Dose Expansion Study of AUR105 NCT05605119 | Aurigene Discovery Technologies Limited | Phase 1 |
| Completed | DT-9081 Study in Participants With Advanced, Recurrent or Metastatic Solid Tumours NCT05582850 | Domain Therapeutics SA | Phase 1 |
| Active Not Recruiting | Personalized Neoantigen Cancer Vaccine for Patients with Solid Tumors NCT06614140 | Seqker Biosciences, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors NCT05544552 | Tyra Biosciences, Inc | Phase 1 / Phase 2 |
| Terminated | A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors NCT05601219 | Adanate, Inc | Phase 1 |
| Unknown | A Study of HS248 in Patients With Advanced Solid Tumors NCT05759234 | Hanhui Pharmaceutical Co., Ltd | Phase 1 |
| Completed | Study of DF9001 in Patients With Advanced Solid Tumors NCT05597839 | Dragonfly Therapeutics | Phase 1 / Phase 2 |
| Completed | Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors NCT05586321 | Genmab | Phase 1 |
| Unknown | U87 CART in Treatment of Advanced Solid Tumor NCT05605197 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Phase 1 |
| Terminated | A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tu NCT05435339 | Genmab | Phase 1 / Phase 2 |
| Completed | Molecular Imaging of EpCAM Receptors Using [99mTc]Tc(CO)3-(HE)3-Ec1 NCT05620472 | Tomsk National Research Medical Center of the Russian Academy of Sciences | Phase 1 |
| Terminated | A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics NCT05607199 | Aurigene Discovery Technologies Limited | Phase 1 |
| Completed | Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy NCT05276284 | Kristoffer Rohrberg | Phase 1 / Phase 2 |
| Withdrawn | 177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malig NCT04315246 | Y-mAbs Therapeutics | Phase 1 / Phase 2 |
| Recruiting | BP1001-A in Patients With Advanced or Recurrent Solid Tumors NCT04196257 | Bio-Path Holdings, Inc. | Phase 1 |
| Recruiting | Advanced or Recurrent Solid Tumors Treated With SHetA2 NCT04928508 | University of Oklahoma | Phase 1 |
| Terminated | A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors NCT05381909 | BeiGene | Phase 1 |
| Terminated | SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mu NCT05480865 | Navire Pharma Inc., a BridgeBio company | Phase 1 |
| Recruiting | An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid a NCT05481502 | Gustave Roussy, Cancer Campus, Grand Paris | N/A |
| Unknown | Universal Germline Testing in the Community NCT05416710 | Invitae Corporation | — |
| Active Not Recruiting | IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor NCT05359445 | Immatics Biotechnologies GmbH | Phase 1 |
| Terminated | A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adu NCT05346484 | Imugene Limited | Phase 1 |
| Completed | Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors NCT05307874 | ImCheck Therapeutics | Phase 1 / Phase 2 |
| Completed | Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors NCT05309187 | Immune-Onc Therapeutics | Phase 1 |
| Unknown | HR Positive, HER2 Negative Advanced Breast Cancer With Progression After Endocrine Therapy NCT05322720 | Taizhou EOC Pharma Co., Ltd. | Phase 2 |
| Terminated | A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alteratio NCT05242822 | Kinnate Biopharma | Phase 1 |
| Unknown | TGFβR-KO CAR-EGFR T Cells in Previously Treated Advanced EGFR-positive Solid Tumors NCT04976218 | Chinese PLA General Hospital | Phase 1 |
| Recruiting | COAST Therapy in Advanced Solid Tumors and Prostate Cancer NCT05036226 | Medical University of South Carolina | Phase 1 / Phase 2 |
| Recruiting | Prospective Cohort With Clinic-biologic Database of Patients Treated by Immunotherapy NCT05223608 | Centre Oscar Lambret | N/A |
| Unknown | Phase 1 First-in-human Study of JS014 NCT05296772 | Anwita Biosciences | Phase 1 |
| Withdrawn | 3D011-08 Monotherapy in Subjects With Advanced Solid Tumors NCT05099536 | 3D Medicines (Beijing) Co., Ltd. | Phase 1 |
| Unknown | Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors NCT05388487 | HighField Biopharmaceuticals Corporation | Phase 1 |
| Completed | Stratification of Patients in Oncogeriatrics and Personalization of Interventions NCT05131113 | Biogipuzkoa Health Research Institute | N/A |
| Completed | A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid NCT05074472 | ZielBio, Inc. | Phase 1 / Phase 2 |
| Recruiting | First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advance NCT05216432 | Relay Therapeutics, Inc. | Phase 1 |
| Completed | Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours NCT05114668 | Kazia Therapeutics Limited | Phase 1 |
| Recruiting | Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing NCT04981119 | A2 Biotherapeutics Inc. | — |
| Completed | Evaluation of the Impact of Chemotherapy on Body Odor in Adolescents and Young Adults in Oncology NCT04899505 | Institut Curie | — |
| Terminated | FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors NCT05069935 | Fate Therapeutics | Phase 1 |
| Completed | A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal NCT05078593 | Shanghai Henlius Biotech | Phase 1 |
| Completed | First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in NCT05054348 | Immune-Onc Therapeutics | Phase 1 |
| Recruiting | Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects W NCT05055609 | Trethera | Phase 1 |
| Recruiting | A Beta-only IL-2 ImmunoTherapY Study NCT05086692 | Medicenna Therapeutics, Inc. | Phase 1 / Phase 2 |
| Suspended | A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Ca NCT04946864 | Ascentage Pharma Group Inc. | Phase 1 / Phase 2 |
| Terminated | 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression NCT04927663 | Rahul Aggarwal | Phase 1 |
| Active Not Recruiting | A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors NCT04913285 | Pierre Fabre Medicament | Phase 1 |
| Unknown | Safety Study of 89Zr-NY001 PET Imaging in Patients NCT04971369 | Wuxi No. 4 People's Hospital | N/A |
| Unknown | Safety Study of 89Zr-Anti-CLDN18.2 mAbs PET Imaging in Patients With CLDN18.2 Positive Solid Tumors NCT04989010 | Wuxi No. 4 People's Hospital | N/A |
| Terminated | Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors NCT04901806 | Pyramid Biosciences | Phase 1 |
| Unknown | A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma NCT04983810 | Cyclacel Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Completed | New Formulation Study of Inupadenant (EOS100850) in Patients with Cancer NCT05117177 | iTeos Therapeutics | Phase 1 |
| Recruiting | Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related NCT04942717 | Memorial Sloan Kettering Cancer Center | N/A |
| Active Not Recruiting | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors NCT04902872 | Cybrexa Therapeutics | Phase 1 / Phase 2 |
| Completed | CYP3A4 Activity in Patients With Prostate Cancer Versus Male Patients With Other Solid Tumours NCT05518799 | The Netherlands Cancer Institute | N/A |
| Unknown | A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors NCT04859777 | Monopteros Therapeutics Inc. | Phase 1 |
| Recruiting | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors NCT03915678 | Institut Bergonié | Phase 2 |
| Recruiting | A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors NCT04673942 | EpicentRx, Inc. | Phase 2 |
| Recruiting | Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors NCT04665206 | Vivace Therapeutics, Inc | Phase 1 / Phase 2 |
| Completed | A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors NCT04761198 | Mereo BioPharma | Phase 1 / Phase 2 |
| Unknown | A Study of of HOT1030 in Patients With Advanced Solid Tumors NCT05060263 | Huabo Biopharm Co., Ltd. | Phase 1 |
| Active Not Recruiting | NeoTIL in Advanced Solid Tumors NCT04643574 | Centre Hospitalier Universitaire Vaudois | Phase 1 |
| Terminated | Pembrolizumab And Lenvatinib In Leptomeningeal Metastases NCT04729348 | Massachusetts General Hospital | Phase 2 |
| Unknown | 89Zr-labeled KN035 PET Imaging in Patients With PD-L1 Positive Solid Tumors NCT04977128 | Wuxi No. 4 People's Hospital | N/A |
| Unknown | A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor NCT05230186 | TScan Therapeutics, Inc. | — |
| Completed | A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic T NCT04814667 | Centre Leon Berard | — |
| Active Not Recruiting | Developing a Virtual Stress Management Intervention for Spousal/Partnered Caregivers of Solid Tumor Cancer Pat NCT04739696 | University of Colorado, Denver | N/A |
| Recruiting | Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignanc NCT04282044 | BioEclipse Therapeutics | Phase 1 |
| Recruiting | Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors NCT04842812 | Second Affiliated Hospital of Guangzhou Medical University | Phase 1 |
| Recruiting | Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors NCT04803318 | Second Affiliated Hospital of Guangzhou Medical University | Phase 2 |
| Completed | Study of HL-085 in Patients With Advanced Solid Tumor Tumors NCT04683354 | Kechow Pharma, Inc. | Phase 1 |
| Active Not Recruiting | First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer NCT04725474 | CatalYm GmbH | Phase 1 / Phase 2 |
| Suspended | Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive So NCT04650451 | Bellicum Pharmaceuticals | Phase 1 |
| Completed | Study on Skin Toxicities Induced by Cancer Treatments NCT04402606 | Institut Curie | N/A |
| Recruiting | Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs NCT04770207 | Second Affiliated Hospital of Guangzhou Medical University | Phase 2 |
| Completed | A Study of AK112 for Advanced Solid Tumors NCT04597541 | Akeso | Phase 1 / Phase 2 |
| Completed | EXPLORATORY STUDY Addendum to INVAC1-CT-101 (NCT02301754) NCT04515043 | Invectys | Phase 1 |
| Active Not Recruiting | Study to Evaluate D-1553 in Subjects With Solid Tumors NCT04585035 | InventisBio Co., Ltd | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies NCT04552288 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Terminated | FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors NCT04551885 | Fate Therapeutics | Phase 1 |
| Completed | A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tum NCT04474470 | TyrNovo Ltd. | Phase 1 / Phase 2 |
| Recruiting | HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma NCT04353375 | Hutchmed | Phase 2 / Phase 3 |
| Completed | Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors NCT04121442 | Buzzard Pharmaceuticals | Phase 1 / Phase 2 |
| Unknown | Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors NCT04556669 | Hebei Senlang Biotechnology Inc., Ltd. | Phase 1 |
| Unknown | Systematic Evaluation of Human Explant Model Systems Engineering NCT04671654 | University Hospital Heidelberg | — |
| Completed | A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects. NCT04428086 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Unknown | Improving Cyberknife Spinal Stereotactic Radiotherapy in Difficult to Treat Cases (IMPRESS) NCT05252975 | Royal Marsden NHS Foundation Trust | N/A |
| Recruiting | A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors NCT04219254 | BioInvent International AB | Phase 1 / Phase 2 |
| Recruiting | An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With NCT04443088 | Shenzhen Ionova Life Sciences Co., Ltd. | Phase 1 |
| Completed | Epidemiological Features and Clinical Course of COVID -19 Infection in Cancer Patients: The Rovid Study NCT04811781 | Istituto Oncologico Veneto IRCCS | — |
| Completed | Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors NCT04504942 | CytoDyn, Inc. | Phase 2 |
| Completed | TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers NCT04306900 | Trishula Therapeutics, Inc. | Phase 1 |
| Active Not Recruiting | First-in-Human Study of ICT01 in Patients With Advanced Cancer NCT04243499 | ImCheck Therapeutics | Phase 1 / Phase 2 |
| Unknown | Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Statu NCT04169178 | Henlix, Inc | Phase 1 |
| Active Not Recruiting | A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers NCT04328844 | iOnctura | Phase 1 |
| Completed | Impact of ICU on the Quality of Life in Cancer Patients NCT04310033 | University Hospital, Grenoble | — |
| Withdrawn | PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Sol NCT03706274 | CytomX Therapeutics | Phase 1 |
| Completed | A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Adva NCT04200963 | Ikena Oncology | Phase 1 |
| Recruiting | Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors NCT04165772 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | Effectiveness of Pharmacist Intervention on Capecitabine Relative Dose Intensity, Adherence, Knowledge & Safet NCT04175899 | Ministry of Health, Malaysia | N/A |
| Completed | A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT) NCT04105335 | Mina Alpha Limited | Phase 1 |
| Suspended | Paclitaxel Therapeutic Drug Monitoring in Cancer Patients NCT03987555 | Wake Forest University Health Sciences | — |
| Completed | Study of DF1001 in Patients With Advanced Solid Tumors NCT04143711 | Dragonfly Therapeutics | Phase 1 / Phase 2 |
| Recruiting | Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies NCT04092673 | Effector Therapeutics | Phase 1 / Phase 2 |
| Active Not Recruiting | Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors NCT04041310 | Nouscom SRL | Phase 1 / Phase 2 |
| Recruiting | Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab NCT04130516 | Linnaeus Therapeutics, Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors NCT04165330 | Sarcoma Oncology Research Center, LLC | Phase 1 / Phase 2 |
| Unknown | Feasibility of a Process of Digital Validation of Chemotherapies in a Day Treatment Unit NCT03977766 | Institut Paoli-Calmettes | N/A |
| Completed | Safety and Efficacy Study of IMSA101 in Refractory Malignancies NCT04020185 | ImmuneSensor Therapeutics Inc. | Phase 1 / Phase 2 |
| Terminated | Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors NCT03992326 | Centre Hospitalier Universitaire Vaudois | Phase 1 |
| Active Not Recruiting | A Monotherapy in Subjects With Advanced Solid Tumors NCT04221204 | 3D Medicines (Beijing) Co., Ltd. | Phase 1 |
| Completed | A Phase 1 Study of NOV1601(CHC2014) in Adult Subjects With Solid Organ Malignancies NCT04014257 | Handok Inc. | Phase 1 |
| Terminated | The Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol NCT03892018 | Athenex, Inc. | Phase 1 |
| Unknown | Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors NCT04053673 | Ribon Therapeutics, Inc. | Phase 1 |
| Completed | Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to NCT03941262 | NKGen Biotech, Inc. | Phase 1 |
| Completed | Study of FCN-437c in Patients With Advanced Solid Tumors NCT03951116 | Fochon Pharmaceuticals, Ltd. | Phase 1 |
| Terminated | Phase I Study of HL-085 in Patients With Advanced Solid Tumors NCT03976050 | Shanghai Kechow Pharma, Inc. | Phase 1 |
| Completed | Phase 1a Study to Evaluate Immunogenicity of ASV® NCT03673020 | Agenus Inc. | Phase 1 |
| Recruiting | ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Sol NCT03686124 | Immatics US, Inc. | Phase 1 / Phase 2 |
| Completed | A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies NCT03922204 | Merus B.V. | Phase 1 |
| Completed | TCR-engineered T Cells in Solid Tumors: IMA202-101 NCT03441100 | Immatics US, Inc. | Phase 1 |
| Recruiting | Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca NCT03919292 | Virginia Commonwealth University | Phase 1 / Phase 2 |
| Completed | Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participant NCT03905148 | BeiGene | Phase 1 |
| Completed | A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours NCT03990233 | OSE Immunotherapeutics | Phase 1 |
| Recruiting | Intravital Microscopy in Human Solid Tumors NCT03823144 | Mayo Clinic | N/A |
| Completed | First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer NCT03873883 | iTeos Therapeutics | Phase 1 |
| Completed | RACIN in Patients With Advanced TIL-negative Solid Tumors NCT03728179 | Centre Hospitalier Universitaire Vaudois | Phase 1 |
| Recruiting | Psychotherapy Intervention for Latinos With Adv Cancer NCT04537936 | Memorial Sloan Kettering Cancer Center | N/A |
| Withdrawn | Yoga for Solid Tumor NCT03728205 | Abramson Cancer Center at Penn Medicine | N/A |
| Completed | MGD019 DART® Protein in Unresectable/Metastatic Cancer NCT03761017 | MacroGenics | Phase 1 |
| Completed | Cannabis Use in Cancer Patients NCT03617692 | University of Colorado, Denver | — |
| Recruiting | Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignanc NCT03772561 | National University Hospital, Singapore | Phase 1 |
| Recruiting | TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors NCT03778814 | Second Affiliated Hospital of Guangzhou Medical University | Phase 1 |
| Unknown | 89Zr-KN035 PET Imaging in Patients With Advanced Solid Tumors NCT03638804 | The First Affiliated Hospital of Soochow University | N/A |
| Unknown | Study of PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells With the Conditioning of PC in Mesothelin Posit NCT03747965 | Chinese PLA General Hospital | Phase 1 |
| Completed | Phase I Study of EOC202 Plus Paclitaxel in Chinese Patients With Metastatic Breast Cancer NCT03600090 | Taizhou EOC Pharma Co., Ltd. | Phase 1 |
| Withdrawn | Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors NCT03496519 | University of Colorado, Denver | Phase 1 |
| Unknown | Advanced Refractory Solid Tumors With TP53 Mutations Register Study NCT03927599 | Tianjin Medical University Second Hospital | — |
| Completed | A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk NCT03573310 | Janssen Research & Development, LLC | Phase 1 |
| Recruiting | A Study of HQP1351 in Patients With GIST or Other Solid Tumors NCT03594422 | Ascentage Pharma Group Inc. | Phase 1 |
| Completed | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With S NCT03543813 | CytomX Therapeutics | Phase 1 / Phase 2 |
| Completed | A Study of CS3006 in Subjects with Locally Advanced or Metastatic Solid Tumors NCT03516123 | CStone Pharmaceuticals | Phase 1 |
| Completed | Study of ASTX029 in Subjects With Advanced Solid Tumors NCT03520075 | Taiho Oncology, Inc. | Phase 1 / Phase 2 |
| Unknown | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors NCT03475953 | Institut Bergonié | Phase 1 / Phase 2 |
| Recruiting | Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With NCT03465592 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 / Phase 2 |
| Completed | A Study of CS1002 in Subjects with Advanced Solid Tumors NCT03523819 | CStone Pharmaceuticals | Phase 1 |
| Terminated | A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor- NCT03494231 | Henlix, Inc | Phase 1 |
| Unknown | Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With M NCT03545815 | Chinese PLA General Hospital | Phase 1 |
| Completed | Comparison of Humeral or Thoracic Implantation of an Central Veinous Access by an Implantable Venous Access De NCT03410121 | Center Eugene Marquis | N/A |
| Unknown | IMX-110 in Patients With Advanced Solid Tumors NCT03382340 | Immix Biopharma Australia Pty Ltd | Phase 1 / Phase 2 |
| Unknown | Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors NCT03398720 | Jiangsu HengRui Medicine Co., Ltd. | Phase 1 |
| Completed | K-BASKET, TAS-117, PI3K/AKT Gene Aberration NCT03017521 | Yonsei University | Phase 2 |
| Terminated | A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced So NCT03355066 | Biosplice Therapeutics, Inc. | Phase 1 |
| Completed | Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors NCT03274661 | Baptist Health South Florida | Phase 2 |
| Completed | Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors NCT03360734 | Glycotope GmbH | Phase 1 |
| Terminated | Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignanci NCT03209401 | Georgetown University | Phase 1 |
| Completed | Circulating Tumor DNA As Liquid Biopsy in Patients with Stage IV Solid Tumors, a Feasibility Study At MUSC HCC NCT03302325 | Medical University of South Carolina | — |
| Withdrawn | Absorption and Excretion of Oral Docetaxel NCT05242926 | Modra Pharmaceuticals | Phase 1 |
| Completed | Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours NCT03008018 | Karus Therapeutics Limited | Phase 1 |
| Completed | Telatinib Safety and Pharmacokinetics Study in China Patients With Advanced Solid Tumors NCT03175497 | Taizhou EOC Pharma Co., Ltd. | Phase 1 |
| Withdrawn | Oral Docetaxel in Patients With Normal or Impaired Liver Function NCT05084456 | Modra Pharmaceuticals | Phase 1 |
| Unknown | POA Prospective Repository NCT03324841 | Caris Science, Inc. | — |
| Unknown | Personalized Therapy of Molecular Tumor Board Participation With the Guidance of Next Generation Sequencing NCT03929653 | Tianjin Medical University Second Hospital | — |
| Terminated | PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With S NCT03149549 | CytomX Therapeutics | Phase 1 / Phase 2 |
| Completed | A Study of AK-01 (LY3295668) in Solid Tumors NCT03092934 | Eli Lilly and Company | Phase 1 / Phase 2 |
| Completed | SHIVA02 - Evaluation of the Efficacy of Targeted Therapy Based on Tumor Molecular Profiling in Patients With A NCT03084757 | Institut Curie | N/A |
| Unknown | A Study of HMPL-453 in Patients With Advanced Solid Malignancies NCT03160833 | Hutchison Medipharma Limited | Phase 1 / Phase 2 |
| Completed | Food Effect Study of ModraDoc006 in Combination With Ritonavir NCT03147378 | Modra Pharmaceuticals | Phase 1 |
| Completed | Interest of Reticulocyte Haemoglobin Content (RET-he) in Management of Functional Anemia for Patient With Soli NCT03656172 | Institut Cancerologie de l'Ouest | — |
| Completed | A Phase I Study of SH003 for Evaluate Safe Dose Range in Patients With Solid Cancer NCT03081819 | Kyunghee University Medical Center | Phase 1 |
| Unknown | PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies NCT03030001 | Ningbo Cancer Hospital | Phase 1 / Phase 2 |
| Terminated | AVID100 in Advanced Epithelial Carcinomas NCT03094169 | Formation Biologics | Phase 1 / Phase 2 |
| Active Not Recruiting | A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) NCT02974738 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 |
| Unknown | POA Retrospective Repository NCT03326479 | Caris Science, Inc. | — |
| Unknown | A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours NCT02977364 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 |
| Completed | 18F-FDG Uptake Measurements in Malignant Solid Tumors on PET/CT and PET/MR NCT02717572 | Washington University School of Medicine | Phase 1 |
| Completed | Perfusion-Induced Hyperthermia for Metastatic Carcinoma NCT02409108 | Jonathan Kiev | N/A |
| Recruiting | Psychotherapy Intervention for Latinos With Advanced Cancer NCT04015609 | Memorial Sloan Kettering Cancer Center | N/A |
| Recruiting | The PEACE (Posthumous Evaluation of Advanced Cancer Environment) Study NCT03004755 | University College, London | — |
| Completed | Testing Two Different Intensities of an Intervention to Enhance REsilience and to Reduce SupportIve Care Needs NCT03045003 | Manuela Eicher | N/A |
| Completed | Circulating Tumor Cells in Solid Tumors NCT03161821 | UNC Lineberger Comprehensive Cancer Center | — |
| Completed | Evaluation of Different Analysis Methods for Circulating Tumor Cells, Circulating Endothelial Cell, and Circul NCT02220556 | Institut Curie | N/A |
| Recruiting | A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor NCT00571389 | BioCytics, Inc. | — |
| No Longer Available | Expanded Access Neoantigen Vaccine in Solid Tumors NCT03914872 | Washington University School of Medicine | — |
| Available | MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer NCT06980506 | Monopar Therapeutics | — |